Anika Therapeutics SG&A Expense (Semi Annual) Analysis

Anika Therapeutics, Inc. (ANIK)

15.02 +0.22 (+1.49%) USD | NASDAQ | Apr 06, 11:05

View SG&A Expense (Semi Annual) for ANIK.
Upgrade now.

Sep '18

Jan '19

May '19

285.00

270.00

255.00

240.00

View SG&A Expense (Semi Annual) Chart

Start Trial

View Historical Data

Start Trial

View SG&A Expense (Semi Annual) Range, Past 5 Years

Start Trial

Minimum

Maximum

Average

Median

View SG&A Expense (Semi Annual) Benchmarks

Start Trial

BioCryst Pharmaceuticals, Inc.	--
Lantheus Holdings, Inc.	--
TELA Bio, Inc.	--
Plus Therapeutics, Inc.	--
BioStem Technologies, Inc.	--